B2M and chronic kidney disease: Current screening standards including measurement of eGFR and urinary biomarkers such as beta-2 microglobulin and kidney injury molecule (KIM-1) are widely used for CDK detection, but it is difficult to predict CKD precisely.23 Evidence-based medicine requires gender heterogeneity to be taken into account in CKD deterioration to inform the risk assessment, monitoring, and prognosis.